The Fibrin Pad Liver Study

PHASE3CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

October 31, 2011

Conditions
Hemorrhage
Interventions
BIOLOGICAL

Fibrin Pad

Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).

PROCEDURE

Standard of Care

Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.

Trial Locations (9)

1010

Auckland City Hospital, Grafton

3044

The Alfred, Melbourne

5011

Queen Elizabeth Hospital, Woodville

5042

Flinders Medical Centre, Bedford Park

9713

University Medical Center, Groningen

D-66421

University Hospital of the University of Saarland, Straße

B15 2TH

Queen Elizabeth Hospital, Birmingham

CB2 0QQ

Addenbrookes Hospital, Cambridge

EH16 4SA

Royal Infirmary of Edinburgh, Edinburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

OMRIX Biopharmaceuticals

INDUSTRY

lead

Ethicon, Inc.

INDUSTRY

NCT01166243 - The Fibrin Pad Liver Study | Biotech Hunter | Biotech Hunter